Is Windlas Biotech good?

Is Windlas Biotech good?

1. Is Windlas Biotech Ltd a good quality company? Past 10 year’s financial track record analysis by Moneyworks4me indicates that Windlas Biotech Ltd is a average quality company.

Is Windlas biotech profitable?

Over FY19-21, Windlas Biotech’s revenue and operating profit has grown at a CAGR of 18-19%. Contract manufacturing offers significant opportunities for growth too.

What is product of Windlas biotech?

About Us. Windlas Biotech Ltd – Manufacturer of melphalan tablets ip, metformin hcl & pharmaceutical tablet & capsules in Dehradun, Uttarakhand.

Is Windlas biotech debt free?

At present, the company has around Rs 30 crore of debt. After the IPO, the debt is expected to be down by Rs 10 crore. Gupta added that the company despite debt has enough liquidity. Windlas Biotech has Rs 55 crore in banks, mutual funds and other liquid instruments.

Who owns Windlas Biotech?

Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass and the Promoter Trust are the promoters of the company, having a total shareholding of 70.20 percent of the pre-offer paid-up equity share capital. Vivek Dhariwal is the Chairman and Non-Executive Independent Director of the company.

See also  How do you become a global mobility specialist?

What is grey market premium of Windlas Biotech?

Windlas Biotech shares were available at Rs 80-85 or 17.4-18.5 percent premium in the grey market, resulting into a price of Rs 540-545 against issue price of Rs 460 per share, the IPO Watch and IPO Central data showed.

Is Windlas IPO good?

The offer received bids for 13.74 crore shares as against 61.36 lakh shares on offer. The initial public offer of Windlas Biotech received bids for 13.78 crore shares as against 61.36 lakh shares on offer, according to stock exchange data.

How is Windlas Biotech IPO?

The IPO was subscribed 22 times wherein the portion reserved for Qualified Institutional Buyers was subscribed 24.4 times and portion for Retail Individual Investors was subscribed 24.27 times. Windlas Biotech’s ₹ 401.5 crore IPO comprised a fresh issue of ₹ 165 crore and an offer for sale worth ₹ 236.5 crore.

Which is best IPO to buy today?

Find the best IPO shares of 2022 based on their performance calculated with IPO offer price and current market price….Top 10 IPO in India 2022 (By Performance)

Company Name Adani Wilmar Limited
Issue Price (Rs) 230
Current Price at BSE (Rs) 585.40
Current Price at NSE (Rs) 715.95
Gain (%) 154.52

What is business of Windlas Biotech?

Windlas Biotech Private Limited manufactures drugs for human consumption. The Company markets wet and dry granulation, micronization and milling dosing, bi-layer tablets, hard capsules, pressurized and vacuum vessels, non-aqueous solvents, powder, pellets, and pediatric formulations.

What IPO should I invest in August?

That said, if you wish to invest in any of the above IPOs, having a demat account is mandatory….Upcoming IPOs in August 2021.

See also  What is the use of Power BI dataflow?
Name of the company Opening date of the IPO Closing date of the IPO
Windlas Biotech August 04, 2021 August 06, 2021
Devyani International August 04, 2021 August 06, 2021

Is Windlas Biotech good for long term?

Most experts Moneycontrol spoke to advise holding Windlas Biotech shares for the long term while short-term investors can book profits. As for Exxaro, the advise booking profits.

Can I buy Windlas Biotech IPO?

Windlas Biotech Limited is launching its IPO. The public offering comprises a fresh issue of equity shares aggregating up to Rs. 165 crores and an offer for sale of 51.4 lakh equity shares from selling shareholders….Windlas Biotech IPO Closed.

IPO date 04 Aug 2021 – 06 Aug 2021
Minimum order quantity 30
(D)RHP View

Should you subscribe to Windlas Biotech IPO?

The Windlas IPO is at the higher end of the closest industry (API manufacturers) valuation range. The valuation hinges on the company sustaining its historical bottom line growth at around 20 per cent in the medium-term. Long term investors need not subscribe to the IPO now.

What will be listing price of Windlas Biotech?

Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India….Windlas Biotech IPO Listing Date.

Listing Date Monday, August 16, 2021
IPO Price ₹460 per share
Face Value ₹5 per share

Who can buy shares in GREY market?

As it’s over the counter market, there are no official people or business you can approach for IPO Grey Market trading. If you are interested in buying or selling IPO stocks in Grey Market, you have to find a local dealer who can find buyers or sellers for you.

See also  What is the full meaning of various?

How do I buy gray market IPO?

Buyers place the order to buy IPO shares at a certain premium by contacting the grey market dealers. Next, the dealer contacts the sellers who applied in the IPO and ask them if they are willing to sell their IPO shares at a certain premium at this time.

Add a Comment